Lancet Interesting articles: Nov 29, 2025 issue

[Prash]

  

ADVERTISEMENT

In this issue of The Lancet:

Vol. 406 Number 10519 | Nov 29, 2025 | p 2509-2600

My Account Subscribe Authors About

Twitter Podcast

FEATURES Evidence to Impact Award Now open for applications! We’re looking for intersectoral teams using implementation science to bridge the gap between evidence and real-world health impact. Learn more about the Award, including how to apply. Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial Open Access Read this Article Editorial The Global Fund and the future of global health Comment Uniting academies of medicine on climate and health Transfemoral TMVR: turning promise into practice New light on the activators of factor XI in venous thromboembolism Personalised prevention therapy in type 1 diabetes The new America First Global Health Strategy goes back to the future China's commitment to advancing gender equality Offline: Is there really a trust crisis in science? World Report Amid massive cuts, Global Fund raises $11 billion Aid cuts: Tanzania looks to boost domestic financing Perspectives Rohini Mathur: using health data to tackle health inequalities From doing science to saving science Words and silence The eleventh commandment Obituary Susan Xenarios Correspondence Catch-up growth after switch to asciminib in a twin with chronic myeloid leukaemia The impact of war on the respiratory health of civilians in Gaza When professional associations fail public health Views on the upcoming Lancet Commission on disability and health Views on the upcoming Lancet Commission on disability and health Views on the upcoming Lancet Commission on disability and health – Authors' reply HCV response-guided therapy: is shorter always better? HCV response-guided therapy: is shorter always better? – Authors' reply Department of Error Department of Error Articles Percutaneous transcatheter valve replacement in individuals with mitral regurgitation unsuitable for surgery or transcatheter edge-to-edge repair: a prospective, multicountry, single-arm trial Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial Open Access Review Contemporary, non-invasive imaging diagnosis of chronic coronary artery disease Health care in the USA: money has become the mission

View the entire Table of Contents online

CONTENT Online First Commissions Series MULTIMEDIA Infographics Podcasts Videos INFO & SERVICES Lancet Alerts Open Access Publishing excellence

The best science for better lives

Copyright © 2025 Elsevier Limited except certain content provided by third parties. The Lancet is a trade mark of Elsevier Limited.

--

Prashanth N Suravajhala, Ph.D.

Professor, Systems Genomics Group

Department of Biosciences, Room # 323D, AB-3 

Manipal University Jaipur, Dehmi Kalan 303007,  India.

Founder, Bioclues.org

Group page: http://www.bioinformatics.org/wiki/Prash 

Twitter: @prashbio

"One rule is important in science- only courageous people win "   ~ Max Planck